National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Pregabalin (Lyrica®) for the treatment of Generalised Anxiety Disorder.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
12/09/2014 15/12/2014 Reimbursement Not Recommended at Current Price

 

The NCPE Review Group concludes that, at the current price, pregabalin (Lyrica®) is not cost effective as a first line treatment for generalised anxiety disorder. Pregabalin may be considered cost effective (as a third line treatment) in patients who have relapsed or who have not responded to cognitive behavioural therapy (first line treatment) and who subsequently have relapsed or have not responded to escitalopram or venlaflaxine (first linedrug treatment).

Summary